InnoCore Pharmaceuticals

InnoCore Pharmaceuticals is a specialized drug delivery company focused on advancing long-acting injectable (LAI) technologies for complex molecules like peptides and biologics. Its core asset is the SynBiosys® platform, a patented, biocompatible polymer system capable of sustaining drug release for up to six months. Operating as a private, service-oriented partner, InnoCore collaborates with global pharma and biotech clients to develop and scale customized LAI products across multiple therapeutic areas, from feasibility through commercialization.

SynBiosys®: A proprietary, customizable, bioresorbable polymeric drug delivery platform for creating long-acting injectable (LAI) dosage forms (microspheres, implants, in-situ depots). It is designed to protect fragile peptides and biologics, enabling sustained release for up to 6 months with high API activity retention.

InnoCore competes with other drug delivery specialists and CDMOs offering sustained-release technologies, such as Evonik (with its RESOMER® polymers), Alkermes, and smaller niche players. Its differentiation lies in its deep expertise specifically with fragile peptides/biologics, its customizable SynBiosys® platform, and its proven track record in taking programs from feasibility to clinic.